Star Ratings: The Real Musculoskeletal ROI for Payers

If you’re a payer analyst looking at a new musculoskeletal (MSK) program, you’re going to hear a lot about potential savings and better patient outcomes. The real economic truth, though, especially for programs with an AI component, isn’t found in those stories. It’s in the documented Star Ratings record. That’s the only way to figure out which AI platforms actually move the needle in a value-based care contract.

The Star Ratings system gives you a way to evaluate a health tech platform’s real impact, which is exactly what you need for Capitation and Accountable Care Organization (ACO) models. You can’t just go on anecdotes of patient success. You need verifiable performance metrics. For an MSK program, this is simple: its financial survival depends entirely on producing and documenting outcomes that hit the specific targets payers set in their value-based contracts. No docs, no deal.

Documenting the Musculoskeletal Program Record

An MSK program has to prove its value to a payer, and that proof is all about documentation. This can’t just be marketing claims of efficacy. It has to be objective, verifiable data that aligns with the metrics driving value-based care. The Centers for Medicare & Medicaid Services (CMS) Star Ratings system gives everyone the structure for this evaluation, because it’s all about quality and performance. CMS Star Ratings methodology

You can see how this plays out in Capitation and ACO models. In a capitated setup, providers get a flat fee per patient, so they have every reason to keep that population healthy and out of the hospital efficiently. ACOs work differently, letting providers share in the savings they create by improving care and cutting costs. In either model, if you’re going to plug in an AI health solution, you need to see a clear, documented impact on those goals. Otherwise, what’s the point?

Capitation and ACOs: The Recorded Signal for Value

Payment models like Capitation and ACOs completely change the financial incentives for providers and, in turn, for the AI health platforms they use. Under a capitation contract, an MSK program has to show it can lower total costs for its patient group without letting quality slip. For an ACO, it’s about contributing to measurable cost reductions and quality gains so the organization can hit its shared savings targets. The pressure is on the platform to perform. Health Affairs article on VBC payment models

An AI health platform can’t even get in the door to talk about these models unless it brings published, peer-reviewed outcomes data. That’s the price of admission for a value-based care contract. If a vendor shows up without that kind of evidence, their claims about helping are just speculation, and no payer can responsibly include them in a risk-bearing arrangement.

The Recorded Star Ratings Set: Hinge Health, iRhythm Technologies, and Omada Health

You can see this playing out with a few specific vendors who keep showing up in materials connected to Star Ratings: Hinge Health, iRhythm Technologies, and Omada Health. They work in different areas of health, but they all provide a good picture of how different AI platforms are trying to document their place in value-based care. The fact that they’re even in the conversation about Capitation and ACOs shows how digital health is trying to find its footing in payer economics.

Hinge Health is a big name in digital MSK, and it’s often benchmarked against others. For instance, the digital cardiac platform Hello Heart showed a 3.9x return on investment (ROI), while Hinge Health has reported a 2.4x ROI. Even though this data is from the vendors themselves, this kind of ROI calculation is exactly what gets talked about in value-based care negotiations. Hinge Health’s main competition in the MSK digital health space includes companies like Sword Health.

iRhythm Technologies, which makes cardiac monitoring tech, is another company that comes up when people discuss the need for peer-reviewed data in VBC contracts. The key difference is that iRhythm has actual clinical trial data to back up its claims. That’s a huge step up from the many AI health companies that just publish their own internal “results” without any peer review. RAND Corporation report on digital health evidence

Omada Health is in a similar boat. It provides digital programs for chronic conditions, and it’s being evaluated on how well it fits into payment models like Capitation and shared savings. Just like iRhythm and Hinge Health, Omada is expected to produce measurable outcomes that meet the demands of these contracts. It all comes down to the same thing: value-based care requires auditable clinical results and real cost savings.

What Payers Require: Beyond the Narrative

The takeaway for any payer analyst should be clear: you evaluate an MSK program on its Star Ratings record, not its marketing story. There’s a ratings story, and then there’s a ratings record. Payers need to see hard evidence that an AI health platform can actually deliver what it says it will inside the tight financial constraints of a value-based contract.

When you use the Star Ratings framework to look at an MSK program, you have to start with the documents. That means digging into any available Capitation and ACO materials that name specific vendors. If you can follow the data trail on a company without even having to talk to their sales team, that tells you their documentation is public and verifiable, which is exactly what you want.

So, if an AI health platform wants to get serious about value-based care, its first priority has to be generating and publishing solid, peer-reviewed outcomes data. That commitment to real evidence is what turns a piece of promising tech into a partner a payer can actually work with, one that’s both financially sound and clinically responsible.